New hope for tough prostate cancer: targeted drug combo shows promise

NCT ID NCT03012321

Ongoing Disease control Sponsor: Northwestern University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests two drugs—abiraterone and olaparib—alone or together in men with advanced prostate cancer that has spread and no longer responds to hormone therapy. Only men whose tumors have certain DNA repair defects (like BRCA or ATM mutations) are included. The goal is to see which treatment works best at slowing cancer growth.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: abiraterone acetate, olaparib, and prednisone
What this could lead to: If successful, this could point toward a more effective treatment option for men with advanced prostate cancer that has specific DNA repair defects.
What could go wrong: This is an early phase II trial with only 70 participants, so results may not apply to all patients. The combination may cause more side effects than each drug alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma DNA repair disease metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ABNORMAL DNA REPAIR METASTATIC PROSTATE CARCINOMA PROSTATE CANCER METASTATIC CASTRATION-RESISTANT STAGE IV PROSTATE CANCER

Contacts and locations

Locations

H. Lee Moffitt Cancer Center and Research Institute

Tampa, Florida, 33612, United States
Huntsman Cancer Institute - University of Utah

Salt Lake City, Utah, 84112, United States
Indiana University/ Melvin and Bren Simon Cancer Center

Indianapolis, Indiana, 46202, United States
Kellogg Cancer Center - NorthShore University

Evanston, Illinois, 60201, United States
Northwestern Medicine

Chicago, Illinois, 60611, United States
Rush University Cancer Center

Chicago, Illinois, 60612, United States
Rutgers Cancer Institute of New Jersey

New Brunswick, New Jersey, 08903, United States
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Baltimore, Maryland, 21231, United States
University of California Los Angeles

Los Angeles, California, 90073, United States
University of Chicago

Chicago, Illinois, 60637, United States
University of Michigan Health System

Ann Arbor, Michigan, 48109-5946, United States
University of Michigan Rogel Cancer Center

Detroit, Michigan, 48201, United States
University of North Carolina at Chapel Hill

Chapel Hill, North Carolina, 27514, United States
University of Virginia

Charlottesville, Virginia, 22903, United States
Washington University School of Medicine

St Louis, Missouri, 63110, United States
Weill Cornell Medical College

New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.